Comunicati.net - Comunicati pubblicati - Emilia Romagna Comunicati.net - Comunicati pubblicati - Emilia Romagna Mon, 19 Oct 2020 23:29:17 +0200 Zend_Feed_Writer 1.12.20 (http://framework.zend.com) http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/1 The Endoscopic Submucosal Dissection Market To Go Steady Between 2019 to 2029 Sun, 18 Oct 2020 19:34:58 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666754.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666754.html persistencemarketresearch persistencemarketresearch Endoscopic Submucosal Dissection (ESD) has witnessed slow adoption in Western countries in the past. This is due to the continued referral of patients for surgery or Endoscopic Mucosal Resection (EMR) procedures.

Furthermore, ESD demands highly skilled and trained professionals. Although the procedure is difficult to learn and the training is expensive, a small group of endoscopists in Western countries are becoming more interested. These endoscopists are working toward training in a Japanese center to learn from experts. This change is expected to increase the adoption rate of  endoscopic submucosal dissection  over the coming years.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22897 

Company Profiles

  • Olympus Corporation
  • Boston Scientific Corporation
  • ERBE Elektromedizin GmbH
  • FUJIFILM Medical Systems U.S.A., Inc
  • Sumitomo Bakelite Co., Ltd
  • Ovesco Endoscopy AG
  • ZEON CORPORATION

The global endoscopic submucosal dissection market was valued at US$ 200 Mn in 2018, and is expected to exhibit a healthy CAGR of 7.5% over the estimation period (2019–2029).

Key Takeaways of Endoscopic Submucosal Dissection Market Study

  • ESD is predominantly used for early stomach cancer. This is because the procedure is easy and well-studied for stomach cancer as compared to other gastric cancers. Colorectal cancers are the most complex for ESD procedures, primarily due to the large size of lesions and anatomy of the colon.
  • Specialty clinics are expected to gain traction with the rising adoption of ESD in the Western hemisphere.
  • Endoscopic submucosal dissection knives hold nearly 1/3 market share in the endoscopic submucosal dissection market, followed by tissue retractors. The knives segment is expected to continue holding a relatively similar share through 2029.
  • East Asia, followed by Europe, are the most prominent regions in terms of revenue, due to higher prevalence and adoption of the endoscopic submucosal dissection procedure for gastric cancers.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/22897

"Although East Asia will continue to lead the global endoscopic submucosal dissection market, Western countries such as the US, Germany, and Brazil, along with the Oceania region, are expected to offer lucrative growth opportunities for players in the endoscopic submucosal dissection market. This is primarily due to rising adoption and increasing skilled professionals in these regions, ”  says a PMR analyst.

Acquisitions and Partnerships are Key Strategies of Market Players

Manufacturers in the endoscopic submucosal dissection market are focusing on improving their product portfolios though the launch of new products. Key players are working toward getting new products approved by regulatory bodies and launching them at the earliest.

Some manufacturers are also focused toward the development of other strategies, such as setting up training centers to drive product sales and gain market share, globally. Many endoscopists from Western countries opt for such training programs in East Asia to offer ESD procedures in their countries, such as in the US, Canada, and Brazil.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/22897 

More Valuable Insights on Endoscopic Submucosal Dissection Market

Persistence Market Research offers a unique perspective and actionable insights on the endoscopic submucosal dissection market in its latest study, presenting historical demand assessment of  2014–2018  and projections for  2019–2029 , on basis of product (knives, tissue retractors, grasps / clips, injection agents, and gastroscopes & colonoscopes), indication (esophageal cancer, stomach cancer, and colon cancer), and end user (hospitals, ambulatory surgical centers, and specialty clinics), across seven major regions.

]]>
Worldwide To Create Ripples In The Injectable Drug Delivery Market Between 2019 to 2029 Sun, 18 Oct 2020 19:34:36 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666753.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666753.html persistencemarketresearch persistencemarketresearch Over the years, there has been a rise in the demand for convenient and efficient drug delivery systems for patients that rely on prescription drugs on a regular basis.

This creates a lucrative opportunity for pharmaceutical manufacturers all over the world to develop sophisticated, easy-to-use, and effective injectable drug delivery devices. Moreover, rise in the prevalence of chronic diseases such as diabetes, cancer, and rheumatoid arthritis are likely to fuel the growth of the  injectable drug delivery market  during the forecast period.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/3774 

Company Profiles

  • Eli Lilly and Company
  • Biocon
  • Becton, Dickinson & Company
  • West Pharmaceutical Services, Inc.
  • Johnson & Johnson
  • Antares Pharma
  • AbbVie Inc.
  • Pfizer Inc.
  • Mylan NV
  • Vetter Pharma-Fertigung GmbH & Co.KG
  • Emperra GmbH
  • Digital Medics Pty Ltd
  • Enable Injections LLC
  • Insulet corporation
  • Consort Medical Plc
  • Diabnext
  • Diamesco Co., Ltd
  • SCHOTT AG
  • SiO2 Medical Products
  • Integrity Bio, Inc.
  • Wilhelm Haselmeier GmbH & Co. KG
  • Tandem Diabetes Care
  • Sanofi S.A.
  • Companion Medical Inc.
  • Ypsomed
  • Hoffman - La Roche Ltd.
  • Novo Nordisk A/S
  • Medtronic Plc.

The global injectable drug delivery market was valued at US$ 30.5 Bn in 2018, and is expected to exhibit a CAGR of around 9% during the forecast period (2019–2029).

Key Takeaways of Injectable Drug Delivery Market Study

  • Insulin pens contributed the most share to the injectable drug delivery market in 2018, due to the rising prevalence of diabetes in developing countries.
  • Non-smart injector technology accounted for a prominent share in the global injectable drug delivery market in 2018, due to increase in the adoption of advanced technology and rising demand for smartphone-integrated products.
  • Rise in the demand for connected devices and the high cost of such devices offer growth opportunities for manufacturers of reusable injectable drug delivery devices.
  • Diabetes indication is expected to continue to hold a prominent position in the injectable drug delivery market throughout the forecast period.
  • Increase in the number of pharmaceutical manufacturers has contributed to the dominance of North America in the global injectable drug delivery market.
  • Attributed to growing awareness regarding various diseases such as cancer and diabetes, East Asia is expected to register notable growth opportunities for the injectable drug delivery market.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/3774

“Smart injectable drug delivery devices not only improve patient compliance to treatment but also collect extensive data that is valuable for future research. Rising demand for connected injectable drug delivery devices will offer significant growth opportunity for the injectable drug delivery market,” says a PMR analyst.

Trends in Smart Injectable Drug Delivery Technologies

There are many research and pipeline products that will have the ability to connect with smartphones and trackers. However, current smart products are predominantly available as reusable devices.

This is attributed to the current state of technology that requires further advancements to apply to disposable products. According to a number of studies and key opinion leaders in the industry, there are a number of factors that limit disposable injectable drug delivery devices from being integrated with smart / connecting technologies.

Some of these factors include high cost of Bluetooth integration, low range connectivity with NFC, and lack of power source for connectivity. Thus, although disposable injectable drug delivery will continue holding a larger share throughout the forecast period, reusable injectable drug delivery devices have the potential to grow at a relatively faster rate, at least in the first five years of the forecast period.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/3774 

More Valuable Insights on Injectable Drug Delivery Market

Persistence Market Research offers a unique perspective and actionable insights on the injectable drug delivery market in its latest study.

The report presents historical demand assessment of  2014–2018  and projections for  2019–2029 , on the basis of product (self-injectors, needle-free injectors, auto injectors, wearable injectors, and insulin pens), technology (non-smart injectors and smart injectors), usage (disposable injectors and reusable injectors), indication (anaphylaxis, diabetes, cardiovascular diseases, multiple sclerosis, rheumatoid arthritis, cancer, trauma and emergency, and others), and distribution channel (hospital pharmacies, drug stores, retail pharmacies , and online pharmacies), across seven regions.

]]>
Worldwide To Maintain The Momentum In The Stromal Vascular Fraction Market Between 2019 to 2029 Sun, 18 Oct 2020 19:34:14 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666752.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666752.html persistencemarketresearch persistencemarketresearch Stromal vascular fraction is gaining significant importance in various fields, including internal medicine, orthopedics, plastic and general surgery, and wound healing.

Ease of harvest, abundant availability, and stable phenotype are some factors increasing the demand for stromal vascular fraction. Also, stromal vascular fraction secretes several soluble factors with anti-inflammatory, immunomodulatory, and analgesic effects, which leads to an alternative treatment option for various diseases, significantly benefitting the growth of the  stromal vascular fraction market  during the forecast period.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/20914 

Company Profiles

  • Cytori Therapeutics Inc.
  • IntelliCell BioSciences Inc.
  • Cellular Biomedicines Group, Inc
  • GE Healthcare (Biosafe Group SA)
  • Lifecell Corporation (Allergen PLC)
  • Tissue Genesis Inc
  • InGeneron, Inc.
  • Human med AG
  • MEDICAN CO., LTD

Delivery of stromal vascular fraction by intra-articular injection has advantages over surgical implantation, such as less invasiveness, better patient compliance, and lower cost.

The global stromal vascular fraction market was valued at US$ 76 Mn in 2018, and is expected to witness a CAGR of around 4% over the forecast period (2019-2029).

Key Takeaways of Stromal Vascular Fraction Market Study

  • SVF isolation products have emerged as the largest segment by product, representing 80% of revenue share in the stromal vascular fraction market.
  • The soft tissue segment, under application, contributes a significant market share in the stromal vascular fraction market, owing to the capability to secrete paracrine factors that help in initiating tissue repair and accelerate wound closure.
  • Rising awareness about stem cell therapy for various treatments, increasing volume of cosmetic surgeries performed, and surging demand for aesthetic and reconstructive therapies have contributed to the dominance of North America in the global stromal vascular fraction market.
  • The hospitals segment, under end user, is projected to account for half of the share of the stromal vascular fraction market during the forecast period, as hospitals are highly preferred for the entire process, starting from lipoaspiration, SVF isolation & processing, and finally injecting them at the desired site.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/20914 

"Stromal vascular fraction has emerged as an efficient alternative in the field of regenerative medication. However, better-structured and significant clinical investigations need to be carried out to demonstrate and define the therapeutic potential of stromal vascular fraction,  says a PMR analyst.

Stromal Vascular Fraction Manufacturers Focusing on Innovative Methods to Optimize Tissue Recovery

Consistent up-gradation and innovation in methods to recover adipose tissue-derived mesenchymal stem cells (ATD-MSCs) for autologous use in regenerative medication applications are expected to offer significant opportunities for the stromal vascular fraction market.

For instance, LipoCell from Tissyou, is furnished with a semipermeable film that separates fat tissues from squander components with the assistance of continuous irrigation. The dialysis of the tissue limits the pressure and trauma to the cell and extracellular matrix, evacuating the blood and oil deposits, which are pro-inflammatory.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/20914 

More Valuable Insights on Stromal vascular fraction Market

Persistence Market Research brings a comprehensive research report on the forecasted revenue growth at global, regional, and country levels, and provides an analysis of the latest industry trends in each of the segments from 2014 to 2029.

The global stromal vascular fraction market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader

The study provide compelling insights on the stromal vascular fraction market on basis of product (SVF isolation products, SVF aspirate purification products, and SVF transfer products), application (cosmetic applications, orthopedic applications, soft tissue applications, and others), and end user (hospitals, ambulatory surgical centers, stem cell laboratories, and others), across six major regions.

]]>
Sales Of In The Dural Graft Market To Scale New Heights Between 2019 to 2029 Sun, 18 Oct 2020 19:33:52 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666751.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666751.html persistencemarketresearch persistencemarketresearch Global demand for dural graft is expected to grow significantly, owing to rising burden of neurosurgical diseases leading to increasing cranial and spinal duraplasty, and rapid technological advancements in  dural graft  products.

Moreover, increasing global neurosurgical workforce, extensive clinical research, and increasing demand for CNS dural repair are responsible for increasing the adoption of dural graft products.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25285 

Company Profiles

  • Cook Medical.
  • Integrates Lifesciences Corporation
  • B Braun
  • Cousin Biotech,
  • Natus Medical Incorporated
  • Tissuemed ​​Ltd,
  • Your GmbH
  • Stryker Corporation
  • Medtronic Plc.
  • Johnson & Johnson,
  • Aesculap, Inc.
  • Baxter International Inc

For instance, in 2004, the World Health Organization (WHO) estimated that, there were 33,193 neurosurgeons worldwide, including trainees. Whereas, in 2015, this number rose to approximately 49,940 neurosurgeons, with a 4% total growth, worldwide.

Persistence Market Research predicts that, the global dural graft market will exhibit a 6% CAGR during the forecast period (2019-2029).

Key Takeaways of Dural Graft Market Study

  • By product type, synthetic dural graft along with xenogeneic dural graft are expected to gain traction during the forecast period.
  • Technological advancements in material science of dural graft products in North America and Europe are expected to contribute to the significant dominance of these regions during the forecast period.
  • Brain and spine tumor applications are expected to hold more than 50% share in the global dural graft market.
  • Synthetic polymer material is expected to gain significant traction and experience 2X demand by 2029.
  • Leading dural graft manufacturing companies are partnering with innovative product developers and specialized distributors to strengthen their market position.
  • Rising healthcare expenditure and increasing neurosurgeon workforce density in East Asia are expected to offer significant opportunities for market growth.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25285

"Increasing scientific evidence from industry-led clinical trials and technological advancements in dural graft products are expected to support the significant adoption of synthetic nanofibrous dural grafts." says a PMR analyst.

Brain and Spinal Tumor Application Dominating Dural Graft Market

Prevalence of CNS tumors due to neurological conditions is growing rapidly. Chiari malformation and spinal cord tumor-related neurosurgical procedures requiring dural grafts for surgeries are becoming more frequent. Growing risk of such neurological conditions demands neurosurgical procedures along with duraplasty for effective and safe treatment outcomes.

For instance, in 2018, more than  50%  of dural grafts were used in cranial and spine tumor operations. This high proportion is estimated to continue in the future.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25285 

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the dural graft market in its latest study, presenting historical demand assessment from 2014-2018 and projections for 2019-2029, on the basis of product type (xenogeneic dural graft, synthetic dural graft, autologous dural graft, and allogeneic dural graft), application (brain and spine tumor, traumatic brain and spine injury, cerebrospinal fluid (CSF) accumulation, cerebrovascular accident, epilepsy, and others), material (bovine pericardium, autologous pericardium, synthetic polymers, ligamentum nuchae, and others), and end user (hospitals, ambulatory surgical centers, trauma centers, and clinics), across seven key regions.

]]>
Investments In Innovation To Drive The Autogenous Vaccines Market Between 2019 to 2029 Sun, 18 Oct 2020 19:33:29 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666750.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666750.html persistencemarketresearch persistencemarketresearch Inadequacy of vaccines to combat increasing rare infectious diseases in livestock and companion animals is the key driving factor aiding the growth of the  autogenous vaccines market .

Autogenous vaccines are an efficient alternative to antibiotics that control and prevent infectious diseases. Improvements in animal health, decreased animal suffering, efficient food production, and reduction in the need for antibiotics are boosting the adoption of autogenous vaccines in the livestock industry.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/29491 

Company Profiles

  • Newport Laboratories, Inc.
  • Elanco Animal Health
  • Ceva (Ceva Biovac)
  • Cambridge Technologies
  • Hygieia Biological Laboratories
  • Dyntec sr o
  • Phibro Animal Health Corporation
  • Huvepharma, Inc.
  • Deltamune
  • AniCon Labor GmbH
  • ACE Laboratory Services (Apiam Animal Health)

Increasing animal care spending and research & development activities in the veterinary biologics sector further favours the growth of the autogenous vaccines market.

The global autogenous vaccines market was valued at US$ 428 Mn in 2018, and is expected to witness a CAGR of 4.4% over the forecast period (2019–2029).

Key Takeaways of Autogenous Vaccines Market Study

  • Bacterial strain type contributes more than 3/4 share in the autogenous vaccines market, owing to increasing rare bacterial infections among livestock and companion animals.
  • Veterinary hospitals account for half of the value share in the global autogenous vaccines market, attributed to increase in the number of veterinary hospitals and rising government funding for animal healthcare.
  • Increasing research activities in the veterinary medicine & biologics industry in the United States and rising animal healthcare expenditure have contributed to the dominance of North America in the global autogenous vaccines market.
  • Attributed to growing awareness regarding zoonotic diseases and increasing funding for animal disease eradication, China, Brazil, and India are expected to offer notable growth opportunities for the autogenous vaccines market.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/29491

"Unavailability of licensed vaccines for bacterial and viral infections in animals has directed the focus of several small & large manufactures to invest in the manufacturing of autogenous vaccines, thereby propelling the growth of the autogenous vaccines market,"  says a PMR analyst.

Product Portfolio Expansion through Partnerships - Key Strategy of Leading Autogenous Vaccine Manufacturers

Autogenous vaccine manufacturers are focusing on product portfolio expansion through partnerships with and acquisition of small veterinary biologics manufactures.

For example,  in 2018,  Huvepharma acquired AgriLabs, to expand its presence in the US and speed up the commercialization of biologic products for animal health. The acquisition included AgriLabs's custom vaccines business.

Moreover,  in 2017 , Pharmgate and Cambridge Technologies entered into a strategic alliance to provide commercial, autogenous, and prescription vaccine solutions to veterinarians.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/29491 

More Valuable Insights on Autogenous Vaccines Market

Persistence Market Research offers a unique perspective and actionable insights on autogenous vaccines in its latest study, presenting historical demand assessment from  2014–2018  and projections for  2019–2029,  on the basis of strain type (bacterial strain and virus strain), and end user (veterinary clinics, veterinary hospitals, and veterinary research institutes), across seven major regions.

]]>
Sales Of To Compel The Trans Septal Access Systems Market To Reach Between 2019 to 2029 Sun, 18 Oct 2020 19:33:07 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666749.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666749.html persistencemarketresearch persistencemarketresearch Rising prevalence of obesity, growing geriatric population with higher risk of heart diseases, and rapid technological advancements to detect arrhythmia are critical factors for the growth of the  transseptal access systems market .

Introduction of innovative technologies such as left atrial appendage occlusion therapy is benefitting patients who are at high risk of strokes due to non-valvular atrial fibrillation (AF). These developments not only prolong survival rate, but also reduce morbidity and enhance quality of life.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/18703 

Company Profiles

  • Terumo Corporation
  • Medtronic PLC
  • St. Jude Medical (Abbott Laboratories)
  • Boston Scientific
  • Biosense Webster, Inc. (Johnson & Johnson)
  • Merit Medical Systems, Inc.
  • Baylis Medical Company Inc.
  • Pressure Products Medical Device Manufacturing LLC
  • Cook Medical LLC
  • ransseptal Solutions, Inc.

Moreover, reimbursement coverage for cardiac procedures by private and government healthcare insurance providers is expected to significantly boost the growth of the transseptal access systems market. On back of noteworthy innovations in needles, rapidly increasing sales of transseptal access needles are catalysing market growth.

The global transseptal access systems market was valued at US$ 638 Mn in 2018 and is expected to witness a CAGR of 9.8% during the forecast period (2019–2029).

Key Takeaways of Transseptal Access Systems Market Study

  • Wide adoption of transseptal access sheaths in majority of transseptal procedures for improved left atrium access, tissue contact, maneuverability, and superior clinical outcomes, contributed to the dominance of the segment by product type.
  • Introduction of transseptal access systems for atrial fibrillation ablation   resulted in high success rates for patients with structural heart disease.
  • Owing to rapid installation of transseptal access systems in hospitals for improved healthcare, the segment is expected to hold half of the revenue share in the transseptal access systems market.
  • Increasing incidence of heart-related complexities such as atrial fibrillation, continuous evolving reimbursement scenario by service providers, and availability of various players contributed to the dominance of North America in the global transseptal access systems market.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/18703 

" Launch of new product lines and continuous improvements in available systems have enhanced the safety and efficacy of transseptal access systems. Substantial increase in interest for transseptal heart catheterization is leading to the growth of transseptal access systems market"  says a PMR Analyst.

New Product Launches - Winning Strategy of Leading  Transseptal Access System  Manufacturers

Continuous up-gradation and innovation in transseptal access systems are responsible for intense competition among players in the transseptal access systems market. Numerous organizations are focusing on new product approvals for transseptal access systems.

For example, in  Jan 2019 , Baylis Medical launched ExpanSure, a transseptal access system that combines a dilator and sheath into a single device, which assists in larger dilation as compared to fixed curve sheaths. In  2018 , Transseptal Solutions Ltd received FDA approval for the TSP Crosser Transseptal Access System, which is designed to provide stable catheter positioning and controlled access. These winning strategies by leading players are also being followed by regional and local players.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/18703 

More Valuable Insights on Transseptal Access Systems Market

Persistence Market Research offers a unique perspective and actionable insights on transseptal access systems in its latest study, presenting historical demand assessment from  2014–2018  and projections from  2019–2029 , on the basis of product type (transseptal access sheaths and transseptal access needles), application (AF ablation, MV repair, and LAA occlusion), and end user (hospitals, ambulatory surgical centers, and specialty clinics), across five major regions.

]]>
The Disposable Oral Care Devices Market To Go Strong With Double In% CAGR Between 2019 to 2029 Fri, 16 Oct 2020 09:23:28 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666582.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666582.html persistencemarketresearch persistencemarketresearch An upsurge in the number of hospital-acquired diseases such as pneumonia and other oral infections has created a growth opportunity for manufacturers of  disposable oral care devices . The global disposable oral care products market is set to surpass a valuation of  US $ 4 Bn  by  2029 , as suggested by a new Persistence Market Research (PMR) study.

Increasing demand in East and South Asia, in addition to rising applications in hospitals will primarily drive the sales of disposable oral care products, which are gradually replacing conventional reusable oral care devices. This replacement potential of these devices is attributed to effectiveness in reducing hospital-acquired infections.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31352

Company Profiles

  • 3M Company
  • Dental Technologies Inc.
  • Avanos Medical, Inc. (Halyard Health)
  • Sage Products LLC (Stryker Corporation)
  • Cardinal Health
  • Dynarex Corporation
  • Intersurgical Ltd.
  • McKesson Corporation
  • Medline Industries Inc.
  • Trademark Medical
  • Changzhou Munk Foam Technology Co., Ltd.

Key Takeaways from the Detailed Disposable Oral Products Market Study

  • Oral care kits continue to account for more than 1/3rd market share.
  • Owing to a significant number of in-patient admissions and surging incidences of hospital-acquired pneumonia, hospitals account for nearly half of the global demand.
  • Oral swabs will remain a lucrative product category in disposable oral care products market.
  • North America accounts for a third of overall market value owing to stringent regulatory policies and greater awareness among general population.
  • Due to the rising burden of oral infections and ever-increasing population, East and South Asian markets will display high market growth potential.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/31352

“Factors such as disposable products replacing reusable products, emergence of online sales platforms for medical supplies, and increasing demand for disposable oral care products in intensive care units, are some of the key driving factors for the manufacturers in the disposable oral care devices market,” says the PMR Analyst.

Disposable Oral Devices Market: Competition Overview

The leading and emerging players in the disposable oral care devices market are focusing on acquisition and partnerships with the smaller players and suppliers for expanding their market presence, both economically and geographically. The strategy is prevalent among both the leaders and emerging players.

For instance,

  • Dental Technologies, an emerging player, collaborated with Just Kids Dental to provide preventive healthcare services for high-risk children in Northeastern Minnesota and Northwestern Wisconsin.
  • In  2019 , 3M, a leading player, acquired M * Modal's technology business, which is a leading provider of healthcare solutions powered by artificial intelligence

Stryker Corporation acquired Sage Products from Madison Dearborn Partners. Sage develops, manufactures and distributes disposable products for intensive care unit and hospital inpatient settings.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/31352 

More Valuable Insights on Disposable Oral Care Devices Market

Persistence Market Research offers a unique perspective and actionable insights on disposable oral care devices in its latest study, presenting historical demand assessment from  2014 - 2018  and projections from 2019 - 2029 on basis of product type (oral care kits, ventilator kits, oral swabs, suction swab kits, suction catheter), and end-users (hospitals, nursing homes, specialty clinics, others), across seven major regions.

]]>
"Alopecia Treatment Market To Witness A CAGR Of 4% Between 2020–2036" Fri, 16 Oct 2020 09:23:06 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666581.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666581.html persistencemarketresearch persistencemarketresearch Rising global demand for effective hair loss treatment medications, especially oral drugs, is the prime driver of the global alopecia treatment market. Oral hair loss treatment drugs are gaining immense popularity, as they help in maintaining patient-safety through reduced number of medicine dosages, but with increased drug efficacy. With changing lifestyle along with increase in stress levels among the working class population, cosmeceutical drug manufacturers are focusing on expanding their hair and scalp treatment product lines, and cytokine therapy is gaining momentum for alopecia treatment. These factors are expected to fuel the growth of the alopecia treatment market over the next decade.

The global alopecia treatment market is slated to expand at a CAGR of 4% over the next ten years, to be valued around US$ 9.5 Bn by 2030.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/9677

Companies covered in Alopecia Treatment Market Report

  • Johnson & Johnson, Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Cipla Ltd.
  • Cellmid Ltd.
  • The Himalaya Drug Company
  • Taisho Pharmaceutical Holdings Co., Ltd
  • Shiseido Co., Ltd.
  • Zhangguang 101 Science & Technology Co., Ltd.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/9677

Key Takeaways from Alopecia Treatment Market Study

  • Rising demand for hair loss treatment with minimal side effects is the main drive of the alopecia treatment market.
  • Europe, North America, and Asia Pacific will remain lucrative regions in the global alopecia treatment market through  2030 .
  • The main focus of manufacturers is to innovate and possess cost-effective manufacturing methods to stay ahead of the competition.

"Due to the COVID-19 pandemic, the healthcare community has put all its efforts and resources toward its treatment, and, as such, non-essential medical treatment and procedures have been rescheduled. This will adversely affect the progress of the alopecia treatment market in the short term, ”  says a PMR analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/9677 

Alopecia Treatment  Market: Competition Analysis

Some of the key companies covered in the global alopecia treatment market report include Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd., and Zhangguang 101 Science & Technology Co., Ltd. These companies are primarily focused on enhancing their product portfolios through research & development. They are striving to introduce innovative and cost-effective advanced manufacturing procedures in order to gain a higher market share and thereby strengthen their respective positions in the global market space.

What Else is in the Report?

Persistence Market Research offers a unique perspective and actionable insights on the alopecia treatment market in its latest study, presenting historical demand assessment of  2015 - 2019  and projections for the years  2020 - 2030 . Research of this report has been done based on segmentation into alopecia type (alopecia areata, alopecia totalis, and alopecia universalis), treatment type (topical drugs, oral drugs, injectable drugs, hair transplant services, and low-level laser therapy), and end user (hospitals, dermatologic and trichology clinics, home care settings, and aesthetic clinics), across seven key regions of the world.

]]>
Liposomes Market To Grow At 7% Y-O-Y In Forecast Years 2020–2030 Fri, 16 Oct 2020 09:22:44 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666580.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666580.html persistencemarketresearch persistencemarketresearch Liposomes are a novel system widely used in the field of drug delivery, gene delivery, medical imaging, and model cell membrane biology. Stealth liposome technology, DepoFoam technology, and non-PEGylated liposomal technology are gaining significant adoption in the development of liposome-based products.

Growing research & development activities for the delivery of anti-fungal, anti-cancer, anti-inflammatory drugs, and therapeutic genes are boosting the demand for liposome formulations. Liposomes have the ability to overcome the limitations of conventional therapy and provide benefits in various therapeutic applications, ranging from cancer to pain management. Encapsulation of drugs in liposomes improves the therapeutic indices of various agents.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/16546

Companies covered in Liposomes Market Report

  • Pfizer Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Johnson & Johnson
  • Dr. Reddy’s Laboratories Ltd.
  • Sun Pharma Industries Ltd
  • Baxter AG
  • Sanofi SA
  • Bristol Myers Squibb
  • Mylan NV
  • GlaxoSmithKline Plc.
  • Creative Biolabs
  • Precision NanoSystems Inc.
  • SkyePharma Inc.
  • Luye Pharma Group
  • Encapsula NanoSciences LLC
  • Nanovex Biotechnologies SL
  • Gilead Sciences, Inc.
  • Avanti Polar Lipids, Inc.
  • Fujifilm Holdings Corporation

According to PMR, the global liposomes market was valued at US$ 6.5 Bn in 2019, and is expected to expand at a CAGR of around 7% during the forecast period (20202030).

Key Takeaways from Liposomes Market Study

  • Formulated liposomes occupied nearly 68% of the market value share in the liposomes market in 2019, owing to increasing adoption of liposome-based drug formulations. Doxorubicin and paclitaxel formulated liposomes contributed more than three-fifth of market value share in the global liposomes market.
  • Drug delivery applications accounted the highest market value share in the global liposomes market, on the back of rising demand for nanotechnology drug delivery. The cancer drug delivery application segment is expected to progress at the highest growth rate, due to increasing R&D activities to develop drugs for cancer.
  • Distributional sales hold a major share in the global liposomes market, owing to the growing demand for formulated liposomal drugs.
  • North America holds a prominent revenue share in the global liposomes market, as a result of rising prevalence of cancer and fungal diseases in the region. However, the liposomes market in East Asia is projected to flourish at the highest growth rate, owing to increasing pharmaceutical expenditure in the region.
  •  The race for liposomal vaccine development to combat the ongoing  COVID-19  pandemic is a catalyst for the growth of the global liposomes market.

“Rising demand for liposomal formulations and vaccines, and increasing research activities in the field of biomolecules and gene delivery, are expected to favor the growth of the liposomes market, ”  says a PMR analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/16546 

Product Portfolio Expansion and Regulatory Approval - Key Strategies of Leading Liposome Manufacturers

Manufacturers in the liposomes market are focusing on product portfolio expansion and new product launches. For instance, in  September 2017 , Novartis received EU approval for the Rydapt® (midostaurin) drug for  FLT3 -mutated acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis.

Manufacturers are focusing on acquiring regulatory approval in different countries for the expansion of product sales. For instance, in  October 2017 , GlaxoSmithKline Plc. declared that the US Food and Drug Administration approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles in adults aged  50 years  and above.

More Valuable Insights on Liposomes Market

Persistence Market Research offers a unique perspective and actionable insights on the liposomes market in its latest study, presenting historical demand assessment of  2015 - 2019  and projections for  2020 - 2030, on the basis of product (simple liposomes, formulated liposomes {doxorubicin liposomes, amphotericin B liposomes, paclitaxel liposomes, cytarabine liposomes, irinotecan liposomes, cisplatin liposomes, and others}, and vaccines), application (drug delivery {cancer, fungal infection, viral & parasite infection, and others}, gene delivery / transfection, contrast agents for medical imaging, and model cell membranes), distribution channel (retail sales {academic & research laboratories, biopharmaceutical companies, clinical research organizations, and others} and distributional sales {hospital pharmacies, retail pharmacies, mail order pharmacies, and drug stores}), across seven major regions.

]]>
"Alopecia Treatment Market To Witness A CAGR Of 4% Between 2020–2036" Fri, 16 Oct 2020 09:21:43 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666579.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666579.html persistencemarketresearch persistencemarketresearch Rising global demand for effective hair loss treatment medications, especially oral drugs, is the prime driver of the global alopecia treatment market. Oral hair loss treatment drugs are gaining immense popularity, as they help in maintaining patient-safety through reduced number of medicine dosages, but with increased drug efficacy. With changing lifestyle along with increase in stress levels among the working class population, cosmeceutical drug manufacturers are focusing on expanding their hair and scalp treatment product lines, and cytokine therapy is gaining momentum for alopecia treatment. These factors are expected to fuel the growth of the alopecia treatment market over the next decade.

The global alopecia treatment market is slated to expand at a CAGR of 4% over the next ten years, to be valued around US$ 9.5 Bn by 2030.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/9677

Companies covered in Alopecia Treatment Market Report

  • Johnson & Johnson, Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Cipla Ltd.
  • Cellmid Ltd.
  • The Himalaya Drug Company
  • Taisho Pharmaceutical Holdings Co., Ltd
  • Shiseido Co., Ltd.
  • Zhangguang 101 Science & Technology Co., Ltd.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/9677

Key Takeaways from Alopecia Treatment Market Study

  • Rising demand for hair loss treatment with minimal side effects is the main drive of the alopecia treatment market.
  • Europe, North America, and Asia Pacific will remain lucrative regions in the global alopecia treatment market through  2030 .
  • The main focus of manufacturers is to innovate and possess cost-effective manufacturing methods to stay ahead of the competition.

"Due to the COVID-19 pandemic, the healthcare community has put all its efforts and resources toward its treatment, and, as such, non-essential medical treatment and procedures have been rescheduled. This will adversely affect the progress of the alopecia treatment market in the short term, ”  says a PMR analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/9677 

Alopecia Treatment  Market: Competition Analysis

Some of the key companies covered in the global alopecia treatment market report include Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Johnson & Johnson, Inc., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cellmid Ltd., The Himalaya Drug Company, Taisho Pharmaceutical Holdings Co., Ltd, Shiseido Co., Ltd., and Zhangguang 101 Science & Technology Co., Ltd. These companies are primarily focused on enhancing their product portfolios through research & development. They are striving to introduce innovative and cost-effective advanced manufacturing procedures in order to gain a higher market share and thereby strengthen their respective positions in the global market space.

What Else is in the Report?

Persistence Market Research offers a unique perspective and actionable insights on the alopecia treatment market in its latest study, presenting historical demand assessment of  2015 - 2019  and projections for the years  2020 - 2030 . Research of this report has been done based on segmentation into alopecia type (alopecia areata, alopecia totalis, and alopecia universalis), treatment type (topical drugs, oral drugs, injectable drugs, hair transplant services, and low-level laser therapy), and end user (hospitals, dermatologic and trichology clinics, home care settings, and aesthetic clinics), across seven key regions of the world.

]]>
Liposomes Market To Grow At 7% Y-O-Y In Forecast Years 2020–2030 Fri, 16 Oct 2020 09:21:20 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666578.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666578.html persistencemarketresearch persistencemarketresearch Liposomes are a novel system widely used in the field of drug delivery, gene delivery, medical imaging, and model cell membrane biology. Stealth liposome technology, DepoFoam technology, and non-PEGylated liposomal technology are gaining significant adoption in the development of liposome-based products.

Growing research & development activities for the delivery of anti-fungal, anti-cancer, anti-inflammatory drugs, and therapeutic genes are boosting the demand for liposome formulations. Liposomes have the ability to overcome the limitations of conventional therapy and provide benefits in various therapeutic applications, ranging from cancer to pain management. Encapsulation of drugs in liposomes improves the therapeutic indices of various agents.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/16546

Companies covered in Liposomes Market Report

  • Pfizer Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd
  • Johnson & Johnson
  • Dr. Reddy’s Laboratories Ltd.
  • Sun Pharma Industries Ltd
  • Baxter AG
  • Sanofi SA
  • Bristol Myers Squibb
  • Mylan NV
  • GlaxoSmithKline Plc.
  • Creative Biolabs
  • Precision NanoSystems Inc.
  • SkyePharma Inc.
  • Luye Pharma Group
  • Encapsula NanoSciences LLC
  • Nanovex Biotechnologies SL
  • Gilead Sciences, Inc.
  • Avanti Polar Lipids, Inc.
  • Fujifilm Holdings Corporation

According to PMR, the global liposomes market was valued at US$ 6.5 Bn in 2019, and is expected to expand at a CAGR of around 7% during the forecast period (20202030).

Key Takeaways from Liposomes Market Study

  • Formulated liposomes occupied nearly 68% of the market value share in the liposomes market in 2019, owing to increasing adoption of liposome-based drug formulations. Doxorubicin and paclitaxel formulated liposomes contributed more than three-fifth of market value share in the global liposomes market.
  • Drug delivery applications accounted the highest market value share in the global liposomes market, on the back of rising demand for nanotechnology drug delivery. The cancer drug delivery application segment is expected to progress at the highest growth rate, due to increasing R&D activities to develop drugs for cancer.
  • Distributional sales hold a major share in the global liposomes market, owing to the growing demand for formulated liposomal drugs.
  • North America holds a prominent revenue share in the global liposomes market, as a result of rising prevalence of cancer and fungal diseases in the region. However, the liposomes market in East Asia is projected to flourish at the highest growth rate, owing to increasing pharmaceutical expenditure in the region.
  •  The race for liposomal vaccine development to combat the ongoing  COVID-19  pandemic is a catalyst for the growth of the global liposomes market.

“Rising demand for liposomal formulations and vaccines, and increasing research activities in the field of biomolecules and gene delivery, are expected to favor the growth of the liposomes market, ”  says a PMR analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/16546 

Product Portfolio Expansion and Regulatory Approval - Key Strategies of Leading Liposome Manufacturers

Manufacturers in the liposomes market are focusing on product portfolio expansion and new product launches. For instance, in  September 2017 , Novartis received EU approval for the Rydapt® (midostaurin) drug for  FLT3 -mutated acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis.

Manufacturers are focusing on acquiring regulatory approval in different countries for the expansion of product sales. For instance, in  October 2017 , GlaxoSmithKline Plc. declared that the US Food and Drug Administration approved Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles in adults aged  50 years  and above.

More Valuable Insights on Liposomes Market

Persistence Market Research offers a unique perspective and actionable insights on the liposomes market in its latest study, presenting historical demand assessment of  2015 - 2019  and projections for  2020 - 2030, on the basis of product (simple liposomes, formulated liposomes {doxorubicin liposomes, amphotericin B liposomes, paclitaxel liposomes, cytarabine liposomes, irinotecan liposomes, cisplatin liposomes, and others}, and vaccines), application (drug delivery {cancer, fungal infection, viral & parasite infection, and others}, gene delivery / transfection, contrast agents for medical imaging, and model cell membranes), distribution channel (retail sales {academic & research laboratories, biopharmaceutical companies, clinical research organizations, and others} and distributional sales {hospital pharmacies, retail pharmacies, mail order pharmacies, and drug stores}), across seven major regions.

]]>
The Mammalian Cell Banking Market To Display Growth In Revenue By 14.1% Between 2020–2030 Fri, 16 Oct 2020 09:20:57 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666577.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666577.html persistencemarketresearch persistencemarketresearch Cell banks allow the storage and generation of detailed characterizations of cell lines with specific genomes for research use. Mammalian cells are mostly used in the biopharmaceutical industry for the production of recombinant therapeutic proteins. Moreover, mammalian cell lines are used as host cells for the production of biologics in the biopharmaceutical industry.

The  mammalian cell banking market  is expanding with increasing cancer research. Companies are channelizing efforts to maximize productivity, flexibility, and throughput capabilities. Additionally, with the research community's ever-evolving needs, the demand for specialized cell culture has grown, and due to this, most manufacturers that are currently offering these services cannot depend solely on sales from catalog services.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31663

Companies covered in Mammalian Cell Banking Market Report

  • Sartorius Stedim BioOutsource Limited.
  • Charles River Laboratories.
  • Eurofins DiscoverX Corporation
  • Merck KGaA
  • Lonza Group Ltd
  • VIRUSURE
  • Altogen Labs
  • Abzena Ltd
  • Northway Biotechpharma
  • Selexis SA

According to the latest report published by PMR, the global mammalian cell banking market is projected to account for US$ 1.1 Bn, in terms of value, by 2030 end. The report further projects that the mammalian cell banking market will progress at an average CAGR of 14% through 2030.

 Key Takeaways of Mammalian Cell Banking Market Study      

  • The CHO segment, under cell, is expected to contribute more than 60% of revenue share in the mammalian cell banking market.
  • Various services launched by key players along with customized service offerings are expected to dominate the demand for working cell banks.
  • Leading players in the mammalian cell banking market are collaborating with research institutes as well as contract research organization to strengthen their market position.
  • North America holds more than half of the global mammalian cell banking market share. With increasing use of technology, rapid industrialization, and more research programs, growing economies such East Asia will experience increasing growth in the mammalian cell banking market.
  • Rising demand for cell lines for producing vaccines to combat the  COVID-19  outbreak is boding well for the growth of the mammalian cell banking market.

"The global mammalian cell banking market is expected to witness robust growth during the forecast period. Increase demand for cell banking and its application in cancer research are expected to propel market growth over the next decade, ”  says a PMR analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/31663 

Acquisitions & Partnerships - Key Strategies amongst Market Players

Key players in the mammalian cell banking market are improving their product portfolios and strengthening their market positions though the launch of new products and services.

  • For instance, in  August 2019 , Sartorius Stedim BioOutsource Limited launched a new services for mammalian cell bank manufactures under GMP conditions.
  • In  January 2019 , Charles River Laboratories announced the expansion of cell banking services at its Malvern, PA, site.

Various players in the mammalian cell banking market are focusing on growth strategies such as acquisitions and partnerships.

  • For example, in  June 2019 , Selexis SA announced a partnership with Avacta Group Plc for cell line development.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the mammalian cell banking market in its latest study, presenting historical demand assessment of  2015 - 2019  and projections for  2020 - 2020 , on the basis of cell (CHO, BHK,  NS0 YB2 / 0  &  P2 / 0 HEK293 & derivatives, and HELA), technology (transient expression platforms, inducible expression platforms, and stable expression platforms), cell bank (master cell banks (MCBs), working cell bank (WCBs), End of Production Cell Banks (EoPCBs), and research & development cell banks (R&D CBs)), and end user (contract research organizations (CROs), research & academic institutions, and biopharmaceutical companies), across seven key regions.

]]>
Ineffective Esophageal Motility Treatment Market To Register CAGR 6% Growth In Revenue Between 2020–2030 Fri, 16 Oct 2020 09:20:35 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666576.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666576.html persistencemarketresearch persistencemarketresearch Ineffective esophageal motility treatment leads to a reduction in muscle damage and improved outcomes, improving quality of life and resulting in long-term benefits. Device-based treatment and IEMT drugs have already had a substantial impact on how symptoms of GERD and achalasia are treated.

The first and the most important factor driving the growth of the ineffective esophageal motility treatment market is the increasing prevalence of gastroesophageal reflux disease. Other factors, such as intake of asthma medications and increasing geriatric population, are also responsible for driving the  ineffective esophageal motility treatment market .

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31550 

Companies covered in Ineffective Esophageal Motility Treatment Market Report

  • Johnson & Johnson
  • Mylan Pharmaceutical
  • MediGus Ltd.
  • Torax Medical
  • Medtronic plc.
  • AstraZeneca plc.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc.
  • Bayer AG
  • Pfizer Inc.
  • Bausch Health Companies Inc.
  • LABORIE
  • Mederi Therapeutics, Inc.
  • Becton, Dickinson and Company (C. R. Bard, Inc.)
  • EndoGastric Solutions, Inc
  • Olympus
  • Pentax

According to the latest report published by PMR, the global ineffective esophageal motility treatment market is projected to expand at a decent CAGR of around 6% during the forecast period (20202030).

Key Takeaways from Ineffective Esophageal Motility Treatment Market Study

  • Significant advantages of ineffective esophageal motility treatment; improving reimbursement scenario for surgical treatment devices; increasing awareness regarding gastric reflux disease; and large patient pool for GERD, dysphagia, achalasia, and burning chest pain are key factors propelling the growth of ineffective esophageal motility treatment market in developing regions.
  • North America is a prominent region the global ineffective esophageal motility treatment market, while East Asia is expected to offer lucrative growth opportunities, owing to the large population base and higher incidence of GERD and dysphagia.
  • Higher OTC antacid consumption is poised to drive the growth of the market.
  • Radiofrequency ablation systems with high level precision and procedural advantages over myotomy are expected to generate significant revenue in the long term.
  • Increasing adoption of ineffective esophageal motility treatment drugs for quick recovery as compared to device-based treatment marks higher revenue potential.
  • Raw material procurement issues, drug shortages, and reduced patient visits amidst the COVID-19 pandemic will adversely affect the growth of the ineffective esophageal motility treatment market in the near term.

“Procedural accuracy achieved by treatment devices and affordability of drug-based treatment are anticipated to drive the ineffective esophageal motility treatment market. Additionally, the large patient pool will bring in steady revenue opportunities," says a PMR analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/31550

New Product Launches by Key Players to Strengthen Market Presence

Key manufacturers in the ineffective esophageal motility treatment market are mainly focusing on research & development and introduction new & advanced treatment products. For example, LINX is the new and advanced version of the LINX reflux management device that is used for the transoral incision-less fundoplication process, which is one of the important procedures for the treatment of gastroesophageal reflux disease.

The innovation of new & advanced products is a factor boosting the ineffective esophageal motility treatment market. In addition, Olympus Corporation has launched advanced versions of esophagoscopes, which have improved the treatment curve of gastroesophageal reflux disease. Manufacturers are focusing on extended indication list and higher reimbursement to draw demand and increase profitability.

Alternatively, a key factor affecting the ineffective esophageal motility treatment market is the entry of generic drug manufacturers. Market leaders are constantly working on strengthening their strategies to gain market share.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the ineffective esophageal motility treatment market in its latest study, presenting historical demand assessment of  2015 - 2019  and projections for  2020 - 2030 , on the basis of product (drugs and devices), indication ( GERD, dysphagia, achalasia, and burning chest pain), and end user (institutional sales and retail sales), across seven key regions.

]]>
Continuous Positive Airway Pressure (CPAP) Devices Market To Grow At 6.3% Y-O-Y In Forecast Years 2020–2030 Fri, 16 Oct 2020 09:20:13 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666575.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666575.html persistencemarketresearch persistencemarketresearch Surging adoption of  continuous positive airway pressure (CPAP) devices  for clinical effectiveness of sleep disorders and increasing technological developments in these devices are expected to drive the growth of continuous positive airway pressure devices market. High awareness among the patient population about new diagnosis and availability of CPAP products is likely to impact market growth positively in emerging economies.

Increasing obese population associated with heightened risk of cardiovascular diseases and increasing prevalence of obstructive sleep apnea are primary factors for the growth of the CPAP devices market.

The global continuous positive airway pressure devices market is expected to witness a CAGR of more than 6% during the forecast period (20202030).

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31515

Companies covered in Continuous Positive Airway Pressure Cpap Devices Market Report

  • Medtronic Plc.
  • Smiths Group plc.
  • Koninklijke Philips N.V.
  • Draegerwerk AG & Co. KGaA
  • Fisher & Paykel Healthcare
  • Hamilton Medical AG
  • ResMed Inc.
  • DeVilbiss Healthcare LLC
  • 3B Medical, Inc.
  • BMC Medical Co. Ltd

Due to the COVID 19 pandemic crisis, CPAP has started witnessing greater preference as a potential replacement for lifesaving ventilators after the FDA’s recent emergency policy. Moreover, technological advancements for better diagnosis and management of sleep apnea have been the driving factors for the growth of the continuous positive airway pressure devices market.

Increasing collaborations, R&D investments toward developing technologically-advanced devices, and a refined chain of local distribution networks are expected to boost the growth of the CPAP devices market over the coming years.

Key Takeaways of Continuous Positive Airway Pressure Devices Market Study

  • Based on product, due to superior product efficiency, CPAP devices contributed over 50% market value share in the global continuous positive airway pressure devices market in 2019.
  • Advancements in medical technology have improved the performance of CPAP devices, coupled with several benefits offered such as reduced daytime fatigue, lower blood pressure, and lower risk of heart disease and other medical conditions.
  • Based on application, obstructive sleep apnea contributes 58% of the total market share, and is expected to dominate the space over the forecast period, owing to increasing number of patients with chronic obstructive pulmonary disorders and rapid visible increase in the diagnosis rate of sleep apnea/hypopnea syndrome (SAHS).
  • In terms of end user, hospitals contribute  55%  of the market value share in the global CPAP devices market, due to growing demand for continuous positive airway pressure devices in hospitals and emergency response for better clinical management of sleep apnea.
  • North America holds over  1/3  market value share, and is expected to be the most lucrative regions in the global CPAP devices market during the forecast period.

"Increasing demand for CPAP devices coupled with technological advancements such as improved masks and autotitrating CPAP designs for the effective treatment of sleep disorders are some of the factors expected to aid the growth of the global continuous positive airway pressure devices market over the next decade,"  says a PMR analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/31515 

Collaboration & Launching Products - Imperative Strategy for  Market Players

Market introduction of new continuous positive airway pressure devices and collaboration with various larger as well as regional market players are some of the major factors responsible for intense competition among players in the global continuous positive airway pressure devices market. Most companies in the CPAP devices market are small & medium business enterprises, which limits the competition of market players to specific regions.

For example, in the month of  March 2019 , ResMed completed the acquisition of HB Healthcare (HBH), to help millions in South Korea suffering from sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions. In  May 2017,  Fisher & Paykel launched a new F&P SleepStyle CPAP device that has been designed to use in the diagnosis and treatment of sleep specialists and obstructive sleep apnea or OSA patients.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the continuous positive airway pressure devices market, in its latest study, presenting historical demand assessment of  2015 - 2019  and projections for  2020 - 2030 , based on product (CPAP devices, CPAP humidifiers, and CPAP masks & accessories), application (obstructive sleep apnea, respiratory failures, and others), end user (hospitals, clinics, sleep centers, and home care settings), across seven key regions.

]]>
Call For Inorganic Expansion To Record A CAGR Of 8.3% In The Real-Time PCR (qPCR) Market Between 2020–2030 Fri, 16 Oct 2020 09:19:51 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666574.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666574.html persistencemarketresearch persistencemarketresearch Surging real-time PCR (qPCR) adoption for the diagnosis and estimation of disease-causing microbes due to increasing product availability is expected to drive the growth of the  real-time PCR (qPCR) market . Also, there is high awareness among the patient population about new diagnosis and availability of advanced PCR products.

For instance, in April, 2020, Takara Bio suggested keys to sustenance clinicians and researchers studying the novel coronavirus, such as real-time PCR kits that can be used with recognized primers for complex detection of COVID-19. This is of great importance with the wide spread of the coronavirus that is taking place across the globe, which, in turn, is expected to boost the demand for real-time PCR (qPCR).

Moreover, higher purchasing power and initiation of automated real-time PCR instruments are major factors aiding the growth of the real-time PCR (qPCR) market. Increasing collaborations, R&D investments toward developing kits, reagents, consumables, etc., as effective real-time products, along with a refined chain of local distribution networks are expected to boost market growth.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31513

Companies covered in Real Time Pcr Qpcr Market Report

  • Thermofischer Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Agilent Technologies, Inc.
  • BIOTECON Diagnostics
  • Sigma-Aldrich Co. LLC.
  • Takara Bio Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • QIAGEN N.V.

The global real-time PCR (qPCR) market was valued at US$ 2.8 Bn in 2019, and is expected to exhibit a CAGR of more than 8% during the forecast period (2020–2030).

Key Takeaways of Real-Time PCR (qPCR) Market Study

  • Based on product, due to superior product efficiency, real-time PCR (qPCR) reagents and assays together generated over 42% market value share in 2019.
  • Various product launches by key players along with technological advancements are expected to dominate the demand for real-time PCR (qPCR). For instance, in 2019, Bio-Rad Laboratories, Inc. announced the launch of real-time PCR (qPCR) kits that are named Aspergillus iQ-Check RT-PCR Kits, which are used for the detection of Aspergillus in Cannabis and Cannabis-permeated products.
  • In terms of end user, both, academic and research institutes and biopharmaceutical companies hold over 44% of market value share, due to the growing use of real-time PCR (qPCR) techniques in drug development and other research activities.
  • North America captured over 1/2 real-time PCR (qPCR) market value share, and is expected to be the most lucrative region in the global market during the forecast period. The market in the region is characterized by higher prevalence and diagnosis rates of infectious diseases, and rising awareness regarding advanced real-time PCR (qPCR) devices.

"Increasing adoption of real-time PCR (qPCR) for diagnosis and estimation of disease-causing microbes, along with its cost-effectiveness, and availability of low end products in most of the countries, are some of the factors expected to propel the growth of the global real-time PCR (qPCR) market through 2030, ”  says a PMR analyst.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/31513 

Collaboration & Launching of New Products - An Imperative Strategy for  Market Players

Market introduction of new real-time PCR (qPCR) products and collaboration with various larger as well as regional market players are some of the major factors responsible for the intense competition among real-time PCR (qPCR) market players. Most companies in the real-time PCR (qPCR) market are small & medium business enterprises, which limits the competition of market players to specific regions.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the real-time PCR (qPCR) market in its latest study, presenting historical demand assessment of 2015–2019 and projections for 2020–2030, based on product (real-time PCR (qPCR ) systems, reagents and assays, real-time PCR (qPCR)), application (clinical, research, forensics, and others,), end user (hospitals, diagnostic laboratories, academic and research institutes, biopharmaceutical companies, contract research organizations, animal health, food & agriculture industries, and others), across seven key regions.

]]>
Consumer`s Growing Inclination Towards To Fuel The Growth Of Personal Emergency Response Systems Market Thu, 15 Oct 2020 18:44:28 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666528.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666528.html persistencemarketresearch persistencemarketresearch Rising elderly population and need for continuous patient monitoring have boosted the adoption of personal emergency response systems (PERS), globally. Technological advancements in mobile personal emergency response system devices such as automatic fall detection and medication reminder features are expected to fuel overall personal emergency response systems market growth during the forecast period.

The growing adoption of smartphones by the geriatric population is one of the main factors that supports the introduction of software and applications, as such, enabling the growth of the  personal emergency response systems market .

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/6403 

Company Profiles

  • Koninklijke Philips NV
  • LifeWatch USA
  • Tunstall
  • ADT Inc.
  • Medical Guardian LLC
  • MobileHelp

The global PERS market was valued US$ 4.0 Bn in 2018 and is expected to exhibit a CAGR of 7% during the forecast period (2019–2029).

Key Takeaways of Personal Emergency Response Systems Market Study

  • Landline-associated devices dominated the personal emergency response systems market in terms of revenue, and are expected to hold nearly half of the PERS market share.
  • Wearables and sensor-based transmitters are able to track the location of patients during emergency situations. This feature is expected to be one of the growth driving factors.
  • The demand for personal emergency response systems among home-based users is expected to gain traction during the forecast period.
  • North America is expected to be a significant revenue generating region in the global personal emergency response systems market, owing to the higher adoption rate of these systems by the geriatric population for medication reminder and health monitoring.
  • Innovative product launches are boosting the growth of the personal emergency response systems market.
    • For instance, in December 2019, LifeStation, a leading provider of medical alert monitoring systems for elderly people, launched LifeStation Mobile LTE with a monitoring center of LifeStation, staffed with its team of certified emergency care specialists, enabling seniors to get help quickly.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/6403

"Innovative product launches including remote patient monitoring, fall alerts, rhythmic disorder data, and location tracking, and increase in the adoption rate of these systems among home-based elderly people are expected to stimulate significant market growth." -  says a PMR Analyst.

Improved and Efficient Service Offerings - Strategic Focus of Manufacturers

Key players in the personal emergency response systems market are providing a supporting link between users and emergency healthcare service providers through their products. Care @ Home from Essence Group learns and adapts to an individual's daily behavior, and provides alerts with different levels of severity based on variance from the daily routine. In-Home Medical Alert from Bay Alarm Medical sends alerts to trained emergency operators, family, friends, neighbors, and, if necessary, 911 emergency services, by pressing a button.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/6403 

More Valuable Insights on Personal Emergency Response Systems Market

Persistence Market Research offers a unique perspective and actionable insights on personal emergency response systems in its latest study, presenting historical demand assessment from  2014–2018  and projections for  2019–2029 .

The global personal emergency response systems market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader The study provide compelling insights on the personal emergency response systems market on basis of product type (landline devices, mobile devices, standalone devices, mobile applications), and end user (home-based users, assisted living facilities, hospitals), across five major regions.

]]>
Positivities Regarding Sales Of To Drive The Multiplex Detection Immunoassay Market Thu, 15 Oct 2020 18:44:06 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666527.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666527.html persistencemarketresearch persistencemarketresearch The global  multiplex detection immunoassay market  is set to be valued at over  US $ 2  Bn by 2019  end, with the market expected to exhibit a healthy CAGR during the forecast period  (2019 - 2029) . Rapid, low sample consumption, and cost-effective are features offered by lab-on-chip technology, which is propelling the multiplex detection immunoassay market to new heights.

Several multiplex detection immunoassay products with lab-on-chip technolog y  are currently available in the market for quantitative test of thyroid disorders. For instance, 3D microfluidic chips are used in multiplex bioassays for environmental, clinical and biomedical applications.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/11542

Company Profiles

  • Bio-Rad Laboratories Inc.
  • Thermo Fisher Scientific
  • EMD Millipore (Merck KGaA.
  • Becton, Dickinson and Company.
  • Microsynth AG
  • Quansys Biosciences Inc
  • QIAGEN N.V.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation.
  • Luminex Corporation

Key Takeaways - Multiplex Detection Immunoassay Market Study

  • Minimum quantification and reduced overall reaction time are expected to boost the demand for planar-based multiplex detection immunoassay 2X during the forecast period
  • Among the technique type, protein-based is anticipated to hold large chunk of the multiplex detection immunoassay market
  • Owing to increasing focus on disease predisposition and drug efficacy studies, research and development is expected to gain significant market share in the multiplex detection immunoassay market
  • North America is expected to be significant revenue generator in the multiplex detection immunoassay market owing to emergence of several regional market players and well-developed healthcare infrastructure
  • In terms of end user, pharmaceutical companies are expected to dominate the multiplex detection immunoassay market in terms of revenue

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/11542

Increasing adoption of multiplex detection immunoassay over conventional ELISA as well as technological advancement such as second generation multiplex immunoassay have boosted growth of the multiplex detection immunoassay market.

Increasing Focus on Nanoarrays to Spur Multiplex Detection Immunoassay Market Growth

One of the key factors observed to impact the multiplex detection immunoassay market growth is the development of new and innovative arrays such as Nano arrays. During the last few years, planar-based multiplex detection immunoassay has emerged as a preferred method for clinical diagnosis as well as food contamination detection.

The significant development in nanosciences has taken nano multiplex detection immunoassay arrays to next level, representing ultra-miniaturized version of conventional microarray.

With the development of advanced nano array technology, drug screening process has become more rapid and time effective. These nanoarrays are also being used in the field of proteomics, as these require small amount of sample.

For instance, BioForce Nanosciences launched BioForce NanoArray on which 1,500 different analytes can be measured. Thus, the development of nano multiplex detection immunoassay arrays are anticipated to favor growth of the multiplex detection immunoassay market.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/11542 

Know More About the Report

The multiplex detection immunoassay market, a new study from Persistence Market Research, provides unparalleled insights on evolution of the multiplex detection immunoassay market during  2014 - 2018  and presents demand projections during  2019 - 2029 on the basis of assay type (planar assay, and bead-based assay), technique (nucleic acid-based technique, protein-based technique, and biosensor-based technique), application (disease testing, food contamination testing, research and development, and veterinary disease testing), and end user (pharmaceutical companies, clinical research organizations, food & beverage companies, academic research institutes, diagnostic centers, and biotechnology companies) across prominent regions (North America, Latin America, Europe, South Asia, East Asia , Oceania and MEA).

]]>
The Plasma Surgery Market To Record Remarkable Growth In The Next Decade Thu, 15 Oct 2020 18:43:43 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666526.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666526.html persistencemarketresearch persistencemarketresearch Plasma technology-based cut coagulation and surgical plasma ablation systems have already made significant impact on how ablation procedure is performed and are being widely adopted in modern surgical practices.

A new research study of Persistence Market Research (PMR) suggests that the global market for  plasma surgery  will surpass the revenues worth  US $ 56 Mn  by  2019  end, and there would be healthy adoption of plasma surgery throughout the next decade.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/28726 

Company Profiles

  • Plasma Surgical
  • Mechan Europe Ltd
  • Bovie Medical Corporation (Apyx Medical Corporation)
  • CONMED Corporation

As plasma surgery involves relatively low tissue damage that that after a traditional electrosurgery procedure, this demand will continue to see an upward trend over the following years. Improved outcomes leading to quality life and long-term survival benefits will further contribute to its rapidly rising traction.

Key Takeaways - Plasma Surgery Market Study

  • Significant advantages of plasma surgery system, increasing awareness for plasma technology, improving reimbursement scenarios for surgical reconstruction, and wider indication pool for dissection, coagulation and ablation are key factors influencing the plasma surgery market in developing regions.
  • High upfront cost is posing a negative impact on end users' decision to purchase plasma surgery systems. To resolve this issue, manufacturers are offering plasma surgery systems at a competitive pricing lowering plasma generator cost and probe cost.
  • Plasma ablation systems with high level precision and procedural advantage over laser-guided electrosurgery are expected to generate significant revenue.
  • Increasing adoption of plasma surgery for dissection in ENT intervention as compared to ablation procedure marks higher revenue potential.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/28726 

Fast track approvals for expanded indication for plasma surgery device are expected to renew interest in plasma surgery technology and disrupt the electrosurgical devices business.

Key Players Prioritize Strategic Acquisitions for Regional Stronghold

Key manufacturers are entering the plasma surgery market by strategically focusing on mergers and acquisitions, considering the disruptive technology of these systems. Manufacturers are focusing on expanded indication and application to increase profitability.

In reference to these market changes, another prominent factor affecting the plasma surgery market is the entry of upstream and downstream manufacturers. Market leaders are continuously striving to strengthen their market leadership.

In 2018, Bovie Medical Corporation agreed to sale its core business to Symmetry Surgical Inc. in a deal with an equity value of roughly $ 97 million in cash. With Bovie Medical portfolio, Symmetry acquired Renuvion ™ system, used in cosmetic technology and cosmetic surgery.  

Access Full Report @ https://www.persistencemarketresearch.com/checkout/28726 

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on plasma surgery in its latest study, presenting historical demand assessment from 2014 - 2018 and projections from 2019 - 2029 on the basis of product category (neutral plasma surgery system, plasma ablation systems and cold plasma surgical systems), application (ablation, resection and dissection), and end user (specialty clinics, ambulatory surgical centers and hospitals) in seven key regions.

]]>
Increasing Adoption Of Product To Drive The Arthroscopic Devices Market Thu, 15 Oct 2020 18:43:21 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666525.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666525.html persistencemarketresearch persistencemarketresearch Prominently driven by the increasing adoption in knee osteoarthritis, the  global arthroscopic devices market  is recently witnessing introduction of smaller and technologically advanced arthroscopic devices that have updated optics to match the capabilities of the latest HD systems. This will significantly benefit the growth of the global arthroscopic devices market over the course of following decade.

Integrated Endoscopy, a US-based medical devices company, recently launched its FDA-approved arthroscope NUVIS® with advanced optical design and high-definition visualization features.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/18358 

Company Profiles

  • Arthrex, Inc.
  • Stryker Corporation
  • Smith & Nephew Plc.
  • CONMED Corporation
  • KARL STORZ GmbH & Co. KG
  • Olympus Corporation
  • Richard Wolf GmbH
  • Johnson & Johnson

This unique and battery operated arthroscopic device will effectively resolve the safety and sterility issues of reusable traditional arthroscopes, thereby creating multiple opportunities in the arthroscopic devices market.

Global sales of arthroscopic devices will surpass the market value of US$ 10 Bn by the end of 2029. As indicated by a new Persistence Market Research (PMR) study, arthroscopic devices market is set for a promising CAGR over the course of 2019 - 2029.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/18358

Key Takeaways - Arthroscopic Devices Market Study

  • Small manufacturers of arthroscopic devices are focusing on increasing their global footprint to expand business, internationally. Such activities are expected to fuel the arthroscopic devices market growth during the forecast period.
    • For instance, in October 2018, MinInvasive an Israel based company launched OmniCuff rotator cuff repair system in the U.S. and expanded its business activities internationally.
  • Increasing tie-ups between arthroscopic device manufacturers and distributors to outsource upstream services in emerging markets such as India, are expected to improve sales of arthroscopic devices in these markets.
    • For instance, in November 2016, Stryker Corporation collaborated with Indo UK Institute of Health to deliver affordable arthroscopic care in India.
  • Strategic acquisition of start-ups and mid-sized companies by key arthroscopic device companies to broaden their products and services is expected to propel the arthroscopic devices market growth.
    • For instance, in 2019, Smith & Nephew acquired Ceterix Orthopaedics to enhance its product portfolio. The company added meniscal repair system ‘NovoStitch Pro’ in its product portfolio through this acquisition.
  • North America is expected to be the prominent region in the arthroscopic devices market owing to growing incidences of arthritis knee pain and well-developed medical infrastructure.
    • According to the National Centre for Health Statistics, about 650,000 arthroscopic lavage and debridement procedures are performed for arthritis knee pain each year in the U.S.
  • Rise in arthroscopic device product recalls and retrieving of all faulty and defective arthroscopic device products from the market are restraining the arthroscopic devices market growth.
    • In June 2018, Medicines and Healthcare Products Regulatory Agency (MRHA) UK, sent an urgent field safety notice to Stryker Corporation for initiating a lot-specific recall for Stryker hip implant products to reduce incidences associated with these arthroscopic devices.

Technological advancements such as advanced visualization and improved suturing techniques in arthroscopic devices will result in a market flourishing with ample growth opportunities, providing scope for a competitive advantage to market players in terms of innovation.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/18358 

Who Is Winning?

The arthroscopic devices market report tracks the key market players, which include Arthrex, Inc., Johnson & Johnson, Smith & Nephew Plc., CONMED Corporation, Olympus Corporation, KARL STORZ SE & Co. KG, Stryker Corporation, Richard Wolf GmbH, and others. Leading manufacturers of arthroscopic devices are focusing on collaborations with different organizations to enhance their arthroscopic devices product portfolio especially in sports medicine.

  • For instance, in May 2017, at the Arthroscopic Association of North American Annual Meeting, Stryker's Sport Medicine business announced a collaboration with AlloSource organization to offer high-quality, innovative biologics for sports medicine procedures.

Learn More About the Report Inclusions

Persistence Market Research offers a unique perspective and actionable insights on arthroscopic devices market in its latest study, presenting historical demand assessment from 2014 - 2018 and projections from 2019 - 2029 on the basis of arthroscopic devices product type (arthroscope and arthroscopic systems, arthroscopic shavers, arthroscopy implants, arthroscopy radio frequency systems and wands), and arthroscopic devices end user (hospitals, ambulatory surgical centers, orthopedic clinics) in five key regions.

]]>
Technological Advancements To Expedite The Orally Disintegrating Tablet Market Thu, 15 Oct 2020 18:42:59 +0200 http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666524.html http://content.comunicati.net/comunicati/istituzioni/comuni/emilia_romagna/comune_di_ferrara/666524.html persistencemarketresearch persistencemarketresearch Improvements in drug delivery mechanism offering quicker onset of action with superior bioavailability per dose have transformed characteristics of orally administered drugs with the development of orally disintegrating tablets (ODTs). The  global orally disintegrating tablets market  was valued at nearly  US $ 12 Bn  in  2018  and will exhibit a solid CAGR during the forecast period ( 2019 - 2029 ).

There has been growing preference among consumers and patients for orally disintegrating tablets attributed to increasing applications in treatment of diseases related to central nervous system (CNS), gastrointestinal (GI), cardiovascular disorders, and allergy.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/14572 

Company Profiles

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • AstraZeneca
  • Mylan N.V.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Bausch Health
  • GlaxoSmithKline plc.
  • Sun Pharmaceutical Industries Ltd.
  • Bayer AG
  • Eli Lily and Company
  • Dr. Reddy’s Laboratories Ltd.
  • Takeda Pharmaceutical Company Limited

Bayer’s acquisition of Merck’s consumer care unit was aimed at gaining shares in ODTs. Claritin, an ODT received through this acquisition, was the largest revenue generating drug for allergy in the U.S. that year.

Key Takeaways - Orally Disintegrating Tablets Market Study

  • CNS diseases remain the primary area of application for orally disintegrating tablets. Researchers and healthcare providers are increasingly focusing on medical conditions such as encephalitis, autism, Alzheimer’s disease, schizophrenia, depressive disorders and others to increase the application of orally disintegrating tablets.
  • Formulation process of orally disintegrating tablets is usually patented by manufacturers depending on the technology employed during the production such as lyophilization, freeze drying, and floss formation. Many technologies such as ZYDIS®, LYOC® and QUICKSOLV® are dependent on freeze drying method.
  • Easy disintegration of orally disintegrating tablets in saliva within a few seconds and accuracy of dose as compared to liquid forms and chewable tablet are expected to increase the adoption of ODTs in diseases such as ulcers of throat.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/14572 

Attributed to consumers facing swallowing problems, bitter taste of drugs, and patient incompliance, manufacturers are focusing to improve drug formulations. This would help them gain an edge in terms of innovation, further favoring the growth of orally disintegrating tablets market.

Key Manufacturers Exploring New Business Models

The global orally disintegrating tablets market is fragmented with low entry barriers inspiring generic manufacturers to tap market opportunities in the form of ANDA, arising from the expiry of patent regime of approved drugs.

For instance, Mylan NV launched Lansoprazole DR ODT, a generic version of Takeda's Prevacid® SoluTab DR ODT. The entry of The Himalaya Drug Company LTD. and Banyan Botanicals with new herbal ODT product offerings in next few years is expected to increase product lines and extension in ODTs market.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/14572 

Report Inclusions

Persistence Market Research offers a unique perspective and actionable insights on the Orally Disintegrating Tablets landscape in its new study, presenting historical demand assessment from  2014 - 2018  and projections from  2019 - 2029  on the basis of drug class (anti-psychotics, anti-epileptics, CNS stimulants, anxiolytics, anti-Parkinsonian drugs, anti-hypertensives, NSAIDS, anti-allergy drugs, proton pump inhibitors), disease indication (CNS diseases, GI diseases, allergy, CVS disorders), distribution channel (hospital pharmacies, retail pharmacies, drug stores, online pharmacies), and five key regions.

]]>